Expanded content to advance your research and drug development programs.¹
IO Module
Modules can be ordered at any time, without the burden or delay of sample collection.
*Available in Q2 2023.
ATRi, ataxia telangiectasia mutated and Rad3-related inhibitor; DDRi, DNA damage response inhibitor; EBV, Epstein-Barr virus; HLA, human leukocyte antigen; HomoDel, homozygous deletion; HPV, human papillomavirus; IFN, interferon; IO, immuno-oncology; KIR, killer-cell immunoglobulin-like receptor; LOH, loss of heterozygosity; PARPi, poly (ADP-ribose) polymerase inhibitor.
• HLA and KIR genotyping (germline)
• HLA and IFN copy number loss (somatic: HomDel or LOH)
• Promoter methylation status of IO, HLA, and IFN genes
Uncover novel IO biomarkers with all-in-one somatic and germline variant detection.¹
HRD Module
Identify patients who may respond to PARPi/ATRi/DDRi therapies with additional methylation content.¹
• Better understand gene silencing with promoter methylation status from 24 HRR genes and 170+ tumor suppressor genes
• Genome-wide HRD score*
Viral Module
Confirm viral presence to characterize virally associated tumors (cervical, head, neck, gastric, and esophageal).¹
• EBV virus detection
• HPV virus detection (14 strains, including HPV16 and HPV18)
Home GuardantINFINITY™ FDA Approved Guardant360® CDx Guardant Reveal™ Guardant Infinity Platform™